PMAIP1 and familial pancreatic carcinoma: Research indicated that NOXA/PMAIP1 serves as a marker for an aggressive subtype of pancreatic ductal adenocarcinoma, with NOXA/PMAIP1 expression inducing synthetic lethality upon RUNX1 inhibition in pancreatic cancer (10).